Introduction {#sec1}
============

Itch, like pain, is an aversive sensation that warns us of potential threats to the body ([@bib47; @bib6]). However, itch is a distinct sensation, characterized by the desire to scratch. Although scratching may remove irritants from the skin (providing at least transient relief from itch), it has the paradoxical effect of causing tissue damage that potentiates itch through release of inflammatory mediators. This pathological itch-scratch-itch cycle is a hallmark of chronic pruritus, which can be just as debilitating as chronic pain ([@bib67; @bib73]). Unfortunately, there are few therapeutic options for those that suffer from severe pathological itch. Whereas mu opioids such as morphine are highly effective for the treatment of pain, these drugs actually worsen itch ([@bib20; @bib60]). Thus, there is a great need for better therapies to treat intractable pruritus.

One reason that itch has lagged behind pain in terms of effective therapies is because, until recently, we lacked a clear understanding of how itch is detected and encoded in the nervous system. However, over the last few years there has been much progress in this field. There is now good evidence that MrgprA3-expressing sensory neurons selectively mediate itch, even when activated by the classic algogen capsaicin ([@bib13]). It is very likely that these are not the only itch-selective fibers, since histamine-dependent itch appears to be mediated by a different subset of sensory neurons ([@bib46]). Next, itch seems to be relayed by at least two populations of spinal interneurons---those that express the Npra receptor and those that express the gastrin-releasing peptide receptor (GRPR)---before being conveyed to the brain where it is consciously perceived ([@bib33; @bib59]).

Menthol and other forms of counterstimulation, such as scratching, heat, cool, and noxious agents, provide relief of itch that begins almost instantaneously and lasts from minutes to hours ([@bib66; @bib74; @bib8]). This relief occurs even when the counterstimulus is applied at great distances from the source of itch sensation ([@bib36]). Together, these psychophysical observations suggest that crossmodal inhibition occurs centrally, possibly within the spinal dorsal horn, where sensory information is first integrated and modulated ([@bib62]). The instantaneous relief of itch experienced upon scratching is presumably mediated by a fast-acting neurotransmitter ([@bib4]). In contrast, prolonged inhibition is thought to involve neuromodulators, but the nature of such neuromodulation remains elusive and the neural basis for inhibition of itch by counterstimuli is not known.

We previously generated a mouse model of pathological chronic itch through the constitutive deletion of *Bhlhb5* (also known as *Bhlhe22*), a transcription factor that is transiently expressed in several neuronal subtypes during embryonic and early postnatal development ([@bib48; @bib49]). Through selective ablation, we provided strong evidence that the pathological itch in *Bhlhb5* mutant mice was due to loss of Bhlhb5 in inhibitory neurons in the spinal dorsal horn. Using fate-mapping approaches, we found that *Bhlhb5* mutant mice lack a subset of inhibitory neurons in laminae I and II ([@bib48]). These findings suggested that *Bhlhb5* is essential for the survival of a set of spinal inhibitory interneurons (termed B5-I neurons) that are required for normal itch sensation. However, the identity of B5-I neurons was not clear, and how they inhibit itch was not known.

Here we provide evidence that acute inhibition of B5-I neurons results in elevated itch. We identify and characterize B5-I neurons, showing that they correspond to specific neurochemically defined populations and that they release the kappa opioid dynorphin. Our data suggest that kappa agonists act locally within the spinal cord to selectively reduce itch and not pain. We find that B5-I cells are directly innervated by primary afferents that respond to counterstimuli, such as heat and coolness, which relieve itch in humans. Moreover, we show that menthol inhibits itch in wild-type mice but does not do so in mice lacking B5-I neurons. Thus, B5-I neurons may mediate the inhibition of itch by chemical counterstimuli.

Results {#sec2}
=======

Acute Inhibition of B5-I Cells Results in Elevated Itch {#sec2.1}
-------------------------------------------------------

We previously showed that Bhlhb5 is needed for survival of spinal inhibitory interneurons that are required for normal itch sensation ([@bib48]). To more specifically identify these neurons, we performed coimmunostaining for Bhlhb5 and markers that define distinct populations of spinal interneurons. Bhlhb5 is transiently expressed in ∼7% of neurons in the dorsal horn of mice from embryonic day 13.5 to postnatal day 10 (P10), so we performed these experiments using P4 mice. Consistent with our previous report ([@bib48]), we found that three-quarters of Bhlhb5-expressing neurons in superficial dorsal horn (laminae I and II) are inhibitory, as shown by coexpression of Pax2 ([Figure 1](#fig1){ref-type="fig"}A). We refer to these Bhlhb5-expressing inhibitory interneurons as *B5-I* neurons.

The somatostatin receptor sst~2A~ is exclusive to inhibitory neurons in superficial dorsal horn and is found in ∼50% of the inhibitory interneurons in this region ([@bib43; @bib44; @bib63; @bib72]). To determine whether the B5-I neurons belonged to this subset, we used antibodies against Bhlhb5, Pax2, and sst~2A~. This immunostaining showed that the vast majority of B5-I neurons (∼90%) coexpressed the somatostatin receptor sst~2A~ ([Figures 1](#fig1){ref-type="fig"}A and [S1](#app2){ref-type="sec"}A available online). Furthermore, when we recorded from spinal interneurons genetically labeled with the *Bhlhb5-cre* allele ([@bib48]), half showed strong hyperpolarization in response to somatostatin ([Figure 1](#fig1){ref-type="fig"}B), confirming that B5-I neurons express functional sst~2A~ receptors. Given the loss of B5-I neurons in *Bhlhb5^−/−^* mice, we reasoned that there would be a corresponding decrease in the number of sst~2A~-expressing neurons in these animals. As predicted, the number of sst~2A~-expressing neurons was reduced by two-thirds in *Bhlhb5^−/−^* mice, with no significant change in the number of sst~2A~-negative inhibitory neurons ([Figures 1](#fig1){ref-type="fig"}C and 1D). Thus, the vast majority of B5-I neurons belong to the subset of inhibitory spinal interneurons that express sst~2A~, and a large proportion of the sst~2A~-expressing population is missing in *Bhlhb5^−/−^* mice.

Since somatostatin inhibits neuronal activity and sst~2A~ is the only somatostatin receptor that is expressed by dorsal horn neurons (see <http://www.brain-map.org>), the finding that B5-I neurons express sst~2A~ allowed us to directly test the idea that B5-I neurons normally function to inhibit itch. This experiment was important because, although we had previously shown that loss of B5-I neurons during development is associated with abnormally elevated itch ([@bib48]), the evidence was merely correlative. Specifically, it was not clear whether B5-I neurons function in the adult to inhibit itch, or whether B5-I neurons play a key developmental role in the formation of proper itch circuits. We hypothesized that if B5-I neurons normally function to inhibit itch, then acute inhibition of these neurons by somatostatin would increase itch sensitivity ([Figure 1](#fig1){ref-type="fig"}E). Indeed, upon intrathecal injection of the somatostatin analog octreotide, we observed vigorous scratching, biting, and licking behavior that was suggestive of itch ([Figure 1](#fig1){ref-type="fig"}F), consistent with previous reports ([@bib54]). This spontaneous behavior was dose dependent, with an immediate onset and a duration of approximately half an hour.

Because B5-I neurons account for the majority (two-thirds) of sst~2A~-expressing cells, the finding that acute treatment with octreotide results in elevated scratching behavior is consistent with the hypothesis that B5-I neurons inhibit itch. Nevertheless, it remained possible that the observed scratching behavior was due instead to the effect of octreotide on the one-third of sst~2A~-expressing neurons that are not B5-I neurons. We therefore tested the effect of octreotide on *Bhlhb5^−/−^* mice, which lack B5-I neurons. Specifically, we reasoned that, if octreotide-induced scratching is due to inhibition of B5-I neurons, this treatment would have no effect in mice that lack these cells. As predicted, we observed very little scratching behavior upon intrathecal injection of 100 nM octreotide in *Bhlhb5^−/−^* mice ([Figure 1](#fig1){ref-type="fig"}F). This finding strongly suggests that octreotide-induced itch behavior is due to inhibition of B5-I neurons.

To further assess whether the octreotide-induced scratching was due to elevated itch (rather than a nociceptive response or a grooming behavior), we tested the effect of octreotide on pruritogen-evoked itch. For these experiments, we selected a very low dose of octreotide that had no significant effect on its own (3 ng) and tested its effect on chloroquine-induced itch. We found that intrathecal octreotide significantly increased the amount of time that mice spent biting at the injection site in response to intradermal chloroquine ([Figure 1](#fig1){ref-type="fig"}G). In contrast, this dose of intrathecal octreotide had no effect on acute nociceptive reflexes, as measured by hindpaw withdrawal latency on a hot plate ([Figure S1](#app2){ref-type="sec"}B). Furthermore, the effect of intrathecal octreotide was very likely mediated by spinal neurons (rather than the central terminals of primary afferents) since intradermal octreotide caused no itch-like behavior ([Figure S1](#app2){ref-type="sec"}C). Together, these findings suggest that acute inhibition of B5-I neurons results in elevated itch.

Neurochemical Identification of B5-I Neurons {#sec2.2}
--------------------------------------------

Sst~2A~-expressing inhibitory neurons in laminae I-II can be further subdivided based on the presence or absence of galanin and neuronal nitric oxide synthase (nNOS), which are expressed in mostly nonoverlapping subsets ([Figure 2](#fig2){ref-type="fig"}B; [@bib17; @bib61]). To investigate whether B5-I neurons constitute one or more of these subsets, we performed immunostaining experiments. These experiments revealed that virtually all (∼95%) of the galanin-expressing cells coexpress Bhlhb5 and that these account for 78% of the B5-I neurons ([Figures 2](#fig2){ref-type="fig"}A, left, and [S2](#app2){ref-type="sec"}A). Likewise, many nNOS-expressing neurons coexpress Bhlhb5 (though the number is difficult to assess since nNOS is beginning to be expressed just as Bhlhb5 is being downregulated; [Figures 2](#fig2){ref-type="fig"}A, middle, and [S2](#app2){ref-type="sec"}B). In contrast, Bhlhb5 was very seldom coexpressed with neuropeptide Y (NPY), a marker for a distinct inhibitory subpopulation (2% of NPY cells; [Figures 2](#fig2){ref-type="fig"}A, right, and [S2](#app2){ref-type="sec"}C). These findings suggest that B5-I neurons correspond to two, mostly nonoverlapping subpopulations of inhibitory interneurons: those that express galanin and those that express nNOS.

We next investigated what happens to these populations in the *Bhlhb5^−/−^* mouse. Mice lacking *Bhlhb5* showed a dramatic loss of galanin- and nNOS-expressing populations, but there was no difference in the distribution of two other populations of inhibitory interneurons marked by NPY and parvalbumin, respectively ([Figure S2](#app2){ref-type="sec"}D). To investigate this finding in more detail, we performed a quantitative analysis with the optical disector method ([@bib42]) on sections reacted for sst~2A~, nNOS, galanin, and NeuN and stained with a nuclear marker ([Figures 2](#fig2){ref-type="fig"}B--2D and [S2](#app2){ref-type="sec"}E). In wild-type mice, four subpopulations of sst~2A~-expressing cells were identified: the first coexpressed galanin, a second coexpressed nNOS, a third (small) subpopulation coexpressed both galanin and nNOS, and a fourth expressed neither galanin nor nNOS ([Figure 2](#fig2){ref-type="fig"}B). In the *Bhlhb5^−/−^* mice, galanin-expressing cells were almost completely absent, while the number of sst~2A~-expressing cells that contained nNOS but not galanin was substantially reduced ([Figures 2](#fig2){ref-type="fig"}C and 2D). In contrast, the number of sst~2A~-expressing cells that contained neither galanin nor nNOS did not differ significantly between wild-type and *Bhlhb5^−/−^* mice. This analysis of sst~2A~-expressing interneurons, together with the previous quantification of inhibitory neurons that lack sst~2A~ ([Figure 1](#fig1){ref-type="fig"}D), suggest that the galanin and nNOS populations of inhibitory neurons are severely depleted in *Bhlhb5^−/−^* mice, whereas all other inhibitory populations are unchanged.

B5-I Neurons Express the Kappa Opioid Dynorphin {#sec2.3}
-----------------------------------------------

The loss of galanin cells in the *Bhlhb5^−/−^* mice was of particular interest because these cells also express the kappa opioid dynorphin ([@bib7; @bib52]), and there is precedent for the idea that kappa opioids inhibit itch ([@bib16; @bib21; @bib64]). We therefore confirmed that dynorphin is expressed in B5-I neurons by reacting spinal cords from P4 mice with antibodies against Bhlhb5 and the dynorphin precursor, preprodynorphin (PPD; [Figure 3](#fig3){ref-type="fig"}A). As expected, we found that virtually all dynorphin-expressing neurons in laminae I-II were Bhlhb5 immunoreactive. We also assessed the number of dynorphin-expressing inhibitory interneurons in adult *Bhlhb5^−/−^* animals with antibodies against either PPD or dynorphin B, a cleavage product of the full-length dynorphin peptide. These experiments revealed an almost complete loss of dynorphin-expressing inhibitory interneurons in *Bhlhb5^−/−^* mice ([Figures 3](#fig3){ref-type="fig"}B, 3C, [S3](#app2){ref-type="sec"}B, S3A and S3C), consistent with the finding that galanin-expressing neurons are largely absent in these mice.

Kappa Opioids Inhibit Itch in Response to a Variety of Pruritogens {#sec2.4}
------------------------------------------------------------------

The finding that *Bhlhb5^−/−^* mice lack spinal inhibitory neurons that release dynorphin raised the possibility that B5-I neurons normally inhibit itch in part through activation of the kappa opioid receptor (KOR). As a first step to test this idea, we investigated the effect of kappa agonists nalfurafine and U-50,488 ([Figure 4](#fig4){ref-type="fig"}A; [@bib35; @bib68; @bib69]) on acute pruritogen-evoked itch behavior. To investigate whether kappa agonists inhibit itch mediated by MrgprA3/C11-expressing afferents, we quantified scratch bouts following intradermal injection of chloroquine into the nape of the neck of mice that had been pretreated with either nalfurafine (20 μg/kg) or vehicle. We found that nalfurafine significantly reduced chloroquine-induced itch behavior ([Figures 4](#fig4){ref-type="fig"}B and 4C), consistent with previous findings ([@bib16]). Likewise, nalfurafine significantly attenuated SLIGRL-mediated itch ([Figure 4](#fig4){ref-type="fig"}D). To extend these observations, we tested the effect of U-50,488 (3 mg/kg), a molecularly distinct kappa opioid agonist and observed a similar inhibition of chloroquine- and SLIGRL-induced scratching ([Figures 4](#fig4){ref-type="fig"}B, 4C, and 4D). Thus, kappa agonists inhibit itch mediated by MrgprA3/C11-expressing sensory neurons.

Recent studies have revealed that histamine-induced itch is different than chloroquine-induced itch in that it is mediated by a distinct subset of primary afferents ([@bib46]). We therefore tested the effect of KOR agonists on histamine-induced itch and found that scratching behavior was significantly reduced by nalfurafine, as previously reported ([@bib64]), as well as by U-50,488 ([Figure 4](#fig4){ref-type="fig"}E). Similarly, our experiments revealed that both nalfurafine and U-50,488 significantly reduced serotonin-induced itch ([Figure 4](#fig4){ref-type="fig"}F). Finally, we investigated a dry skin model of itch that develops following daily topical application of acetone/ether followed by water (AEW) ([@bib3; @bib34]). Both kappa agonists significantly reduced spontaneous scratching behavior produced by AEW treatment ([Figure 4](#fig4){ref-type="fig"}G). Importantly, neither U-50,488 (3 mg/kg) nor nalfurafine (20 μg/kg) had any significant effect on rotarod performance, indicating that their effects were not due to motor impairment ([Figure S4](#app2){ref-type="sec"}A). Thus, KOR agonists significantly abate various types of pruritus, including histamine-dependent and histamine-independent itch.

These findings raised the possibility that decreased kappa opioid signaling, due to loss of dynorphin-expressing spinal interneurons, contributes to the abnormally elevated itch in *Bhlhb5^−/−^* mice. Thus, we reasoned that exogenous KOR agonists would relieve abnormal itch in these animals. As observed previously, we found that intradermal injection of chloroquine caused significantly more scratching in *Bhlhb5^−/−^* mice relative to littermate controls ([Figure 4](#fig4){ref-type="fig"}H; [@bib48]). Importantly, pretreatment with nalfurafine almost completely abrogated scratching behavior in *Bhlhb5^−/−^* mice, consistent with the idea that abnormally elevated itch responses in these mice are partly due to decreased kappa tone in spinal cord ([Figure 4](#fig4){ref-type="fig"}H).

A question that remained unclear was whether the elevated itch in *Bhlhb5^−/−^* mice was simply due to the loss of dynorphin, or whether the absence of fast synaptic inhibition from B5-I neurons was also involved. To test whether constitutive loss of dynorphin was sufficient for abnormally elevated itch, we analyzed itch in mice lacking the dynorphin precursor PPD. We found that *PPD^−/−^* mice and their wild-type littermates showed no difference in pruritogen-induced itch behavior ([Figure 4](#fig4){ref-type="fig"}I). This observation suggests that the abnormally elevated itch observed in *Bhlhb5^−/−^* mice is not due to loss of spinal dynorphin alone, hinting at a key role for GABA and/or glycine in the inhibition of itch by B5-I neurons.

A consequence of the loss of B5-I neurons in *Bhlhb5^−/−^* mice is that these mice develop spontaneous skin lesions due to severe pathological itch. To test whether treatment with KOR agonists might provide therapeutic relief for neuropathic itch, we tested these drugs on *Bhlhb5^−/−^* mice with pruritic skin lesions. Systemic treatment with either U-50,488 or nalfurafine significantly reduced the amount of time *Bhlhb5^−/−^* mice spent biting and/or licking the site of lesion by 33% ± 14% and 40% ± 22%, respectively ([Figures S4](#app2){ref-type="sec"}B and S4C), suggesting that kappa opioids have therapeutic potential for neuropathic itch conditions.

Kappa Opioids Are Selective for Itch {#sec2.5}
------------------------------------

Because of the key role of mu opioids in inhibition of pain, numerous groups have assessed the potential role of KOR agonists as analgesics ([@bib18; @bib65]). While KOR agonists were found to be analgesic in some acute, inflammatory, and neuropathic pain tests, their analgesic efficacy at doses that do not affect motor coordination remains unclear ([@bib26; @bib58]). We therefore wondered whether a concentration sufficient to inhibit itch (i.e., 20 μg/kg of nalfurafine) is selective for pruritoception rather than nociception. To address this question, we used the cheek model ([Figures 5](#fig5){ref-type="fig"}A and 5B), in which pruritic agents elicit scratching with the hindlimb, whereas nociceptive substances cause wiping with the forepaw ([@bib55; @bib2]). As expected, intradermal injection of chloroquine into the cheek induced robust hindlimb-mediated scratching with minimal wiping behavior, indicative of itch. Systemic pretreatment with nalfurafine led to an almost complete suppression of scratching, with no significant effect on wiping behavior ([Figures 5](#fig5){ref-type="fig"}C and 5D), in accordance with the idea that kappa agonists inhibit itch.

Next, to investigate the effect of kappa agonists on nociception, we injected capsaicin into the cheek. This treatment evoked intense site-directed wiping with little scratching, in keeping with the idea that pain is the predominant sensation elicited by capsaicin. Importantly, capsaicin-induced wiping was not affected by pretreatment with nalfurafine ([Figure 5](#fig5){ref-type="fig"}F), suggesting that nociceptive responses were unaffected by kappa opioid signaling. In contrast, the modest scratching in response to capsaicin was almost completely abolished following treatment with nalfurafine ([Figure 5](#fig5){ref-type="fig"}E). These results suggest that kappa opioid agonists, at least at low doses, can selectively inhibit itch with no effect on pain.

KOR Agonists and Antagonists Bidirectionally Modulate Itch at the Spinal Cord Level {#sec2.6}
-----------------------------------------------------------------------------------

The finding that systemic kappa opioids inhibit itch, together with our discovery that *Bhlhb5^−/−^* mice lack dynorphin-expressing spinal interneurons, raised the possibility that endogenous dynorphin and exogenous kappa opioids modulate itch through common neural circuits in the spinal cord. To test the idea that the inhibition of itch by kappa opioids is due, at least in part, to activation of spinal KORs, we manipulated KOR signaling in the spinal cord through intrathecal delivery of KOR agonists. Since intrathecal injections allowed us to target dermatomes L3--L5 (corresponding to the hindlimbs), itch behavior was assessed using the calf model ([@bib25]), in which injection of a pruritic agent into the skin elicits a biting response ([Figure 6](#fig6){ref-type="fig"}A). Importantly, we found that intrathecal administration of either U-50,488 (10 μg) or nalfurafine (40 ng) to the lumbar spinal cord significantly reduced chloroquine-evoked biting ([Figure 6](#fig6){ref-type="fig"}B). These findings suggest that activation of KORs in the spinal cord is sufficient to inhibit itch.

A key question is the identity of the cellular targets for kappa opioids within the spinal cord. Though the central processing of itch is not clearly understood, recent work has suggested that itch information is sequentially relayed by at least two types of spinal interneurons (Npra-expressing neurons followed by GRPR-expressing neurons) before being transmitted to the brain ([@bib33]). We therefore investigated whether kappa opioids act upstream or downstream of GRPR-expressing neurons by testing the effect of nalfurafine on GRP-mediated itch. Intrathecal injection of GRP caused robust scratching that was significantly reduced by nalfurafine ([Figure 6](#fig6){ref-type="fig"}C). This finding suggests that kappa agonists mediate their effect (either directly or indirectly) on GRPR-expressing neurons, or on neurons downstream of GRPR activation in the spinal cord.

Next, we reasoned that if B5-I neurons normally release dynorphin to inhibit itch, then blocking endogenous KOR signaling in the dorsal horn might result in elevated itch. To test this idea, we investigated whether treatment with the KOR antagonists norbinaltorphimine (norBNI) or 5′-guanidinonaltrindole (5′GNTI; [Figure 6](#fig6){ref-type="fig"}D) could trigger an enhanced response to chloroquine in the calf. We found that chloroquine-induced biting was significantly increased by intrathecal norBNI. Likewise treatment with 5′GNTI intrathecally increased the amount of chloroquine-induced biting relative to control ([Figure 6](#fig6){ref-type="fig"}E). The finding that blocking KOR signaling increases itch response to chloroquine suggests that endogenous spinal dynorphin normally functions to dampen itch. Together, these results show that modulating opioid tone in the spinal cord can bidirectionally alter itch sensitivity---increasing kappa opioid signaling causes decreased itch, whereas decreasing kappa opioid signaling results in increased itch.

B5-I Neurons Mediate Inhibition of Itch by Chemical Counterstimuli {#sec2.7}
------------------------------------------------------------------

In light of the finding that B5-I neurons function to inhibit itch, we wished to characterize these cells in more detail. We performed patch-clamp recordings from lamina II neurons genetically labeled with the *Bhlhb5-cre* allele ([Figure 7](#fig7){ref-type="fig"}A). Since this allele labels a somewhat broader population than those that we define as B5-I neurons, we used hyperpolarization in response to somatostatin to confirm that we were recording from B5-I neurons. Four basic firing patterns can be identified in lamina II interneurons in response to injection of depolarizing current: tonic, delayed, phasic/transient, and single spiking ([@bib11; @bib14; @bib50]). We found that the majority (29 out of 34) of B5-I neurons showed tonic firing ([Figures 7](#fig7){ref-type="fig"}B and [S5](#app2){ref-type="sec"}A) and may therefore function as integrators. Neurons can be classified based on morphology and previous studies have described several types including vertical, islet, central, and radial, although many cells cannot be classified according to this scheme ([@bib12; @bib71; @bib72]). To determine whether B5-I neurons belonged to any of these subsets, we reconstructed B5-I neurons. Though B5-I neurons did not fit strictly into a single class, the majority were either central or unclassified, with axons and dendrites mainly restricted to lamina II ([Figure 7](#fig7){ref-type="fig"}C). Thus, B5-I neurons are likely to be involved in integrating sensory input within the substantia gelatinosa.

One of the hallmarks of itch is that it is relieved by a variety of counterstimuli, such as scratching, noxious chemicals, or menthol ([@bib8; @bib66; @bib74]). While the neural basis for this phenomenon is unknown, it has been suggested that counterstimuli reduce itch through activation of spinal inhibitory interneurons ([@bib4; @bib30; @bib38; @bib47; @bib6]). Based on our findings, B5-I neurons seemed well positioned to mediate the inhibition of itch by counterstimuli. If so, we reasoned that they would receive input (either directly or indirectly) from primary afferents that mediate the counterstimuli.

Capsaicin, mustard oil, and menthol activate discrete subsets of primary afferents (those that express TrpV1, TrpA1, and TrpM8, respectively). Since topical treatment with any of these substances can inhibit itch, we tested whether B5-I neurons receive input from primary afferents that express TrpV1, TrpA1, or TrpM8 ([Figure 7](#fig7){ref-type="fig"}D). Upon application of capsaicin to depolarize TrpV1-expressing afferents, we saw a significant increase in the frequency of spontaneous excitatory postsynaptic currents (sEPSCs) in 80% (4 of 5) of B5-I neurons, with an average 7.8-fold increase in EPSC frequency ([Figures 7](#fig7){ref-type="fig"}E and 7F). Moreover, a significant increase in mEPSC frequency was likewise observed in the presence of tetrodotoxin (TTX) to block action potential propagation, suggesting that B5-I neurons receive direct input from capsaicin-sensitive sensory neurons ([Figure S5](#app2){ref-type="sec"}B). Similarly, allyl isothiocyanate, a key component of mustard oil, resulted in increased sEPSC frequency in 86% (6 out of 7) B5-I neurons, with an average increase of 3.3-fold ([Figures 7](#fig7){ref-type="fig"}G and 7H). Finally we observed that sEPSC frequency was also significantly increased 2.5-fold by menthol in 90% (9 out of 10) of B5-I neurons ([Figures 7](#fig7){ref-type="fig"}I and 7J). Once again, the increase in mEPSC frequency in response to capsaicin, mustard oil, and menthol was also observed in the presence of tetrodotoxin (TTX) to block action potentials, suggesting that TrpA1- and TrpM8-expressing afferents directly innervate B5-I neurons ([Figures S5](#app2){ref-type="sec"}B, S5C, and S5D).

The finding that B5-I neurons receive direct input from sensory neurons that respond to capsaicin, mustard oil, and menthol is consistent with the idea that B5-I neurons mediate the inhibition of itch by chemical counterstimuli. To directly test this possibility, we developed a mouse model of inhibition of itch by menthol. When wild-type mice were treated with 8% menthol (topically) on the cheek, this caused a significant reduction in subsequent chloroquine-induced scratching. In contrast, *Bhlhb5^−/−^* mice showed no significant inhibition of itch by menthol ([Figure 8](#fig8){ref-type="fig"}A). These findings suggest that B5-I neurons are required for the inhibition of itch by menthol ([Figure 8](#fig8){ref-type="fig"}B).

Discussion {#sec3}
==========

While our everyday experience that itch is relieved by counterstimulation indicates that itch is under inhibitory control, the neural basis for this phenomenon has remained obscure and neuromodulators of itch have not been identified. Here we begin to shed light on this issue by identifying a neuronal subtype in the spinal cord---B5-I neurons---that inhibits itch. We discover that B5-I neurons correspond to specific neurochemical populations and show that they are the major source of the endogenous kappa opioid dynorphin in the dorsal horn. Our data suggest that kappa opioids selectively inhibit itch without affecting pain. Indeed, modulation of kappa opioid tone in the spinal cord can bidirectionally control itch sensitivity, implying that dynorphin acts as a neuromodulator. Finally, we demonstrate that B5-I neurons are innervated by capsaicin-, mustard oil-, and menthol-responsive primary afferents and are required for inhibition of itch by menthol. These data suggest that B5-I neurons mediate the inhibition of itch by chemical counterstimuli ([Figure 8](#fig8){ref-type="fig"}B).

Dorsal Horn Interneurons {#sec3.1}
------------------------

Inhibitory interneurons, which use GABA and/or glycine, account for 25%--30% of neurons in laminae I-II ([@bib41; @bib44]) and are thought to perform several distinct roles in sensory processing ([@bib15; @bib47; @bib51]). To understand how these cells modulate somatosensory input, it is essential to distinguish different functional populations among them ([@bib11; @bib62]). The most widely accepted scheme for classifying superficial dorsal horn interneurons was developed by [@bib12], who identified four main groups, based largely on morphological criteria. However, though others have used this scheme, ∼30% of neurons in these studies could not be classified based on morphology ([@bib14; @bib32; @bib71; @bib72]). Moreover, with the exception of islet cells, inhibitory neurons are morphologically diverse ([@bib72]). Thus, morphology does not appear to be particularly useful for defining inhibitory interneuron subpopulations.

An alternative approach uses the wide array of neuropeptides, receptors, and other proteins that are differentially expressed by dorsal horn neurons ([@bib43; @bib44]). We previously found that ∼50% of inhibitory cells in laminae I-II express sst~2A~, and these can be further subdivided into subpopulations that contain galanin and/or nNOS (which constitute ∼60% of the sst~2A~-expressing cells and therefore approximately one-third of all the inhibitory neurons). The galanin cells coexpress PPD and are the major source of dynorphin in the superficial laminae ([@bib7; @bib52]). In addition, we identified two other nonoverlapping groups among inhibitory interneurons that lack sst~2A~ (NPY- and parvalbumin-expressing cells). There is already evidence that these neurochemical classes differ, both in their responses to noxious stimuli and in their postsynaptic targets ([@bib62; @bib15; @bib44]). The present results provide further evidence in support of this classification scheme, since *Bhlhb5^−/−^* mice show a loss of inhibitory interneurons that is apparently restricted to neurochemically defined populations.

Identification and Characterization of B5-I Neurons {#sec3.2}
---------------------------------------------------

We find that B5-I neurons correspond to two (mostly nonoverlapping) subpopulations---those that coexpress galanin and dynorphin and those that express nNOS. The subpopulation of B5-I neurons that expresses galanin/dynorphin likely uses GABA as its fast transmitter ([@bib56]), whereas the B5-I neurons that express nNOS are thought to release GABA and glycine ([@bib57]). Since relief of itch by counterstimuli begins almost instantaneously, we favor the idea that this component is mediated by fast-acting inhibitory transmitters. In contrast, dynorphin, which modulates neuronal activity via G protein-coupled receptors, may underlie prolonged suppression of itch.

A key finding from our study is that the loss of B5-I neurons (which results in an almost complete absence of dynorphin in the spinal cord) has a different phenotypic outcome than loss of dynorphin alone. Thus, *Bhlhb5^−/−^* mice show dramatically elevated itch, whereas *PPD^−/−^* mice display normal itch sensitivity. This distinction implies that an organism can compensate for the loss of dynorphin, but not for the loss of dynorphin-expressing neurons in the dorsal horn. We speculate that neuromodulatory mechanisms may be particularly amenable to homeostatic compensation ([@bib9]). In keeping with this idea, mice lacking either enkephalin or the mu opioid receptor have subtle pain phenotypes ([@bib22; @bib31]), despite the fact that mu opioids are among the most effective analgesics. Adaptation also occurs in response to chronic opioid overexposure, as shown by the tolerance observed in humans and animal models following long-term treatment with opioid analgesics ([@bib35; @bib69]). These examples underscore the idea that the nervous system is robust in its ability to adjust neural circuit function over time when opioid neuromodulatory function is abnormal. In contrast, neural circuits in the dorsal horn are unable to normalize itch sensitivity when B5-I neurons are lacking, emphasizing the fundamental requirement of this neuronal subtype for the normal manifestation of itch.

B5-I Cells Mediate the Inhibition of Itch by Counterstimuli {#sec3.3}
-----------------------------------------------------------

The idea that spinal interneurons are involved in sharpening acuity between sensory modalities has been proposed by us and others ([@bib30; @bib47; @bib75; @bib45]). In keeping with this idea, conditional loss of VGLUT2 in subsets of primary afferents resulted in mice showing decreased nociceptive responses but heightened pruritic responses, suggesting a role for inhibitory neurons in the suppression of itch by noxious input ([@bib24; @bib28]). However, the specific identity of spinal interneurons that mediate this type of inhibition was unknown. The B5-I neurons that we describe here are well suited for this role since they receive direct input from primary afferents that are known to suppress itch. In addition, we now provide direct evidence that B5-I neurons suppress itch, since acute inhibition of these cells results in spontaneous scratching. Finally, we show that, whereas menthol inhibits itch in wild-type mice, it does not do so in mice that lack B5-I neurons. Together, these data suggest that B5-I neurons mediate the inhibition of itch by menthol and likely other chemical counterstimuli.

Our findings also suggest that specific neuromodulators may be involved in selectively tuning different types of somatosensory input. This has strong precedent elsewhere in the nervous system, where kappa and mu and opioids have distinct (and often opposing) neuromodulatory roles. In the limbic system, mu opioids are euphoric while kappa opioids are dysphoric ([@bib40; @bib53]). In the hypothalamus, mu and kappa opioids have opposing effects on body temperature ([@bib70]). Indeed, mu and kappa receptor-expressing neurons have been found to inhibit one another directly, thereby mediating the mutually antagonistic effects in modulation of pain by the nucleus raphe magnus ([@bib37]). Now parallels are beginning to emerge in the spinal cord, where mu agonists specifically target nociception, and kappa agonists, as we show here, selectively inhibit itch.

Kappa Opioid Agonists as a Treatment for Pruritus {#sec3.4}
-------------------------------------------------

Pruritus is one of the most common adverse effects following spinal administration of mu opioid agonists, affecting \>50% of patients receiving epidural morphine ([@bib19]). Naltrexone, a mu opioid receptor antagonist, is commonly coadministered to reduce the intensity of pruritus, but its use is limited due to its antianalgesic effects ([@bib1]). Interestingly, nalbuphine, a mixed kappa opioid agonist/mu opioid antagonist, is extremely effective in reducing postoperative pruritus ([@bib27]). Unlike naltrexone, nalbuphine does not significantly antagonize the analgesic effects of epidural morphine. This suggests that the ability of nalbuphine to reduce morphine-induced itch is largely due to its KOR agonist activity. Consistent with this, KOR agonists have been shown to reduce morphine-induced itch in monkey ([@bib21]). These findings raise the possibility that coadministration of mu and kappa opioids (or the use of agonists with affinities for both receptors) may offer pain relief without causing itch.

An important question raised by our study is the identity of the dorsal horn neurons that respond to kappa opioids. KORs have been detected on some neurons in laminae I-II ([@bib5]), and approximately 15% of lamina II neurons are hyperpolarized by kappa opioids ([@bib10; @bib39]). While we do not yet know the identity of these cells, our finding that GRP-evoked itch is attenuated by nalfurafine is consistent with the idea that kappa opioids directly inhibit GRPR-expressing spinal interneurons. Alternatively, kappa opioids may act downstream, targeting as-yet-unidentified interneurons or projection neurons that mediate itch. Identifying the dorsal horn neuronal subtype(s) that express the KOR will be of great interest, as these cells may represent a point of convergence between neural circuits mediating itch and those responsible for inhibition of itch by counterstimuli.

Several clinical trials have shown that nalfurafine is effective in reducing itch in patients with chronic renal failure ([@bib23; @bib68]). Furthermore, nalfurafine is well tolerated, and dysphoria is not reported even after 1 year of treatment. Our study provides insight into the mechanism through which kappa agonists inhibit itch, raising the possibility that this class of drugs may be broadly applicable as antipruritics. Thus, kappa agonists may have therapeutic potential for the treatment of pruritus resulting from a wide range of dermatological and systemic diseases.

Experimental Procedures {#sec4}
=======================

Animals and Behavioral Experiments {#sec4.1}
----------------------------------

Most behavioral tests were carried out on 6- to 8-week-old male C57bl/6 mice. Experiments that involved *Bhlhb5^−/−^* mice ([@bib48]) were performed on 4- to 5-week-old mice that did not have skin lesions, unless otherwise stated. To generate age-matched wild-type and *Bhlhb5^−/−^* mice, we harem mated *Bhlhb5^−/+^* mice and wild-type and *Bhlhb5^−/−^* offspring from the resulting litters were used. In all experiments, the observer was blind to genotype and/or treatment. The use of animals was approved by the Institutional Animal Care and Use Committee of the University of Pittsburgh and/or the Ethical Review Process Applications Panel of the University of Glasgow. Experiments performed in A.J.T.'s lab were in accordance with the UK Animals (Scientific Procedures) Act 1986. Further details are provided in the [Supplemental Experimental Procedures](#app2){ref-type="sec"}.

Immunocytochemistry {#sec4.2}
-------------------

Immunocytochemistry was performed using standard protocols. The antibodies used in the study are listed in [Table S1](#app2){ref-type="sec"}, and details of image analysis are given in the [Supplemental Experimental Procedures](#app2){ref-type="sec"}.

Electrophysiology {#sec4.3}
-----------------

Laminectomies were performed on 4- to 6-week-old mice was performed, and the spinal cord was excised to prepare parasagittal or transverse slices. We defined neurons as being sensitive to a particular drug when the synaptic response was altered by more than ±50%. Biocytin-filled cells were reconstructed with Neurolucida (MicroBrightField). Further details are provided in the [Supplemental Experimental Procedures](#app2){ref-type="sec"}.
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![Acute Inhibition of B5-I Cells Results in Elevated Itch\
(A) The inhibitory subset of Bhlhb5-expressing neurons in the superficial dorsal horn (B5-I neurons) coexpress sst~2A~. Spinal cord sections from P4 mice were immunostained to reveal Bhlhb5 (green), sst~2A~ (red), and the inhibitory marker Pax2 (blue). The vast majority (∼90%) of cells expressing Bhlhb5 and Pax2 in laminae I and II colabel with sst~2A~ (arrows). A single confocal optical section through laminae I-IIo is shown. Scale bar, 20 μm.\
(B) Outward current was observed upon application of somatostatin (SST, 1 μM) to 50% of cells with the *Bhlhb5-cre* allele. (Note that the *Bhlhb5-cre* allele also labels other populations including excitatory neurons, which do not respond to SST.)\
(C) The number of sst~2A~-expressing neurons in dorsal horn is significantly diminished in *Bhlhb5^−/−^* mice. Spinal cord sections from 4- to 5-week-old wild-type (top) or *Bhlhb5^−/−^* (bottom) mice were immunostained to reveal sst~2A~ (green) and Pax2 (magenta). Approximately half of the inhibitory (Pax2-expressing) neurons in laminae I and II express sst~2A~ in wild-type mice (arrows), and these cells are dramatically reduced in *Bhlhb5* mutant mice. A single optical section is shown. Scale bar, 50 μm.\
(D) Quantification of (C). There is a significant reduction (^∗^p \< 0.05) in the number of sst~2A~-expressing neurons (sst~2A~ +ve) in laminae I-II of the dorsal horn in *Bhlhb5^−/−^* relative to wild-type (WT), with no significant change (NS) in the number of Pax2-positive inhibitory interneurons that do not express sst~2A~ (sst~2A~ --ve). Data are represented as mean + SD number of cells in laminae I-II per dorsal horn through 100 μm cord taken from L4 (n = 6 mice per genotype, 2 dorsal horns per mouse), analyzed by two-way ANOVA followed by pairwise comparison using the Holm-Sidak method.\
(E) Schematic depicting inhibition of sst~2A~-expressing interneurons with the somatostatin analog octreotide, resulting in elevated itch.\
(F) Intrathecal administration of octreotide (3, 10, 30, or 100 ng in 5 μl vehicle) dose dependently evoked spontaneous scratching behavior in wild-type mice (n = 6--8 mice/treatment). *Bhlhb5^−/−^* mice receiving 100 ng of octreotide intrathecally showed very little scratching response. Intrathecal injections were confirmed by coinjection of 10% methylene blue (n = 8 mice). Total scratching bouts (mean ± SEM) were measured over a 30 min observation period. One-way ANOVA was used to compare mean scratch bouts between treatment groups followed by Tukey's post hoc test (^∗^ indicates significantly different than PBS, p \< 0.05).\
(G) Pruritogen-induced itch behavior was significantly enhanced following intrathecal octreotide (3 ng). Chloroquine (100 μg) was injected intradermally in the calf 30 min after treatment with either octreotide (i.t.) or vehicle (PBS; i.t.). Itch behavior was defined as the cumulative amount of time spent biting/licking the injection site over 30 min. Data are represented as mean ± SEM (^∗^p \< 0.05, Student's t test). Also see [Figure S1](#app2){ref-type="sec"} for the specificity of octreotide-mediated behavioral effects.](gr1){#fig1}

![B5-I Neurons Belong to a Population that Expresses Galanin and/or nNOS\
(A) The vast majority (95.4%, range 95.3%--95.7%, n = 3) of galanin-immunoreactive cells in laminae I-II (magenta) were Bhlhb5 immunoreactive (green; double arrow), and galanin-expressing cells accounted for 78.1% (range: 72.8%--86.4%) of B5-I neurons (image from lamina I-IIo). Numerous nNOS-immunoreactive cells (magenta) coexpress Bhlhb5 (green) as shown by the arrow (n = 3, image from lamina I). NPY seldom colocalized with Bhlhb5 (2.3% of NPY cells, range 1.1%--4.7%, n = 3; arrowheads illustrate cells that do not colocalize, lamina II). Images are single confocal optical sections from mice of indicated ages.\
(B) Populations of inhibitory interneurons in laminae I-II of adult dorsal horn. Approximately 54% of these cells express sst~2A~ (sst~2A~ positive), and these can be further subdivided into classes based on expression of galanin (red), nNOS (blue), galanin and nNOS (magenta), or sst~2A~ only (neither galanin nor nNOS; green). B5-I neurons belong to the classes that express galanin and/or nNOS.\
(C) Single optical sections of laminae I-II from wild-type or *Bhlhb5^−/−^* mice reveal a dramatic loss of the sst~2A~-expressing cells that contain galanin (red, double-headed arrow) and nNOS (blue, arrows), while the sst~2A~-expressing cells that contain neither galanin nor nNOS (sst~2A~ only) are still present (arrowheads). Scale bar, 20 μm.\
(D) Quantification of (C) showing a significant reduction in cells expressing galanin (red), nNOS (blue), and galanin/nNOS (magenta). There was no significant change (NS) in the number of cells expressing sst~2A~ alone (green). Data are represented as mean + SD number of cells in laminae I-II per dorsal horn through 100 μm cord taken from L4 (n = 6 mice, genotype, 2 dorsal horns/mouse), analyzed by two-way ANOVA followed by pairwise comparison using the Holm-Sidak method (^∗^ indicates p \< 0.05). See [Figure S2](#app2){ref-type="sec"} for large field views.](gr2){#fig2}

![B5-I Neurons Express Dynorphin\
(A) Spinal cord sections from P4 mice (n = 3) were immunostained to reveal Bhlhb5 (green), PPD (red), and Pax2 (blue). Virtually all (99%, range 98%--100%) cells expressing PPD and Pax2 were Bhlhb5 immunoreactive (arrows), and these accounted for the majority (85%, range 82.3%--87.95%) of B5-I cells at P4. Asterisk indicates a B5-I cell that does not express PPD. Pax2-negative Bhlhb5-expressing cells (presumed excitatory cells) are indicated with arrowheads. Scale bar, 20 μm. Similar results were observed using antibodies directed against Dynorphin B ([Figure S3](#app2){ref-type="sec"}).\
(B) Spinal cord sections from 4- to 5-week-old wild-type (left) or *Bhlhb5^−/−^* (right) mice immunostained for sst~2A~ (green) and PPD (magenta). In wild-type mice, dynorphin is expressed in a subset of sst~2A~-expressing neurons (arrows), whereas in *Bhlhb5^−/−^* mice, the sst~2A~-expressing neurons that remain lack dynorphin (arrowheads). Images are single confocal optical sections.\
(C) Quantification of (B) showing reduction in the mean number of dynorphin-expressing cells in laminae I and II in *Bhlhb5^−/−^* mice compared to wild-type controls. Data are represented as mean + SD number of cells per dorsal horn through 100 μm cord taken from L4 (n = 3 mice/genotype) and were analyzed by Student's t test (^∗^ indicates p \< 0.05). Also see [Figure S3](#app2){ref-type="sec"}.](gr3){#fig3}

![Systemic Administration of U-50,488 or Nalfurafine Inhibits Scratching Behavior\
(A) Molecular structure of two KOR agonists, U-50,488 and nalfurafine (also called TRK-820).\
(B--F) Pretreatment with U-50,488 (3 mg/kg) or nalfurafine (20 μg/kg) significantly attenuates scratching following intradermal injection of chloroquine (200 μg) (B and C), SLIGRL (100 nM) (D), Histamine (100 μg) (E), or 5-HT (30 μg) (F) relative to control (PBS). Data are represented as mean + SEM number of scratch bouts during the first 40 min after pruritogen injection (n = 8 mice/treatment). For (B), (D), (E), and (F), data were analyzed by one-way ANOVA and Tukey's post hoc test; ^∗^p \< 0.05. For (C), data were analyzed by two-way ANOVA and Tukey's post hoc test; significant effects (p \< 0.05) of U-50,488 (^∗^) and nalfurafine (\#) are indicated.\
(G) Spontaneous scratching induced by AEW treatment was significantly reduced in mice pretreated with either U-50,488 or nalfurafine compared to controls receiving vehicle (PBS). Data are represented as mean + SEM number of scratch bouts recorded over a 1 hr observation period (n = 8 mice/treatment). Data were analyzed by one-way ANOVA and Tukey's post hoc test; ^∗^p \< 0.05.\
(H) Pretreatment with nalfurafine (20 μg/kg) significantly attenuated chloroquine-induced scratching behavior in both wild-type (WT; \#p \< 0.05) and *Bhlhb5^−/−^* (†p \< 0.05) mice. ^∗^ indicates significant difference (p \< 0.05) in chloroquine-induced scratching between WT and *Bhlhb5^−/−^* mice. Experiments were performed using 4-week-old littermate pairs, prior to development of skin lesions (n = 8 mice/treatment). Data were analyzed by two-way ANOVA and Tukey's post hoc test.\
(I) Itch sensitivity in constitutive *preprodynorphin^−/−^* (*PPD^−/−^*) mice ([@bib29]) was analyzed by measuring the response to an intradermal injection of chloroquine into the nape of the neck. Scratching behavior did not significantly differ between treatment groups (n = 7 mice/genotype), suggesting that *PPD^−/−^* mice respond normally to acute pruritic stimuli. Data are represented as mean + SEM, and significance was assessed using a Student's t test.](gr4){#fig4}

![Kappa Agonists Selectively Inhibit Itch- but Not Pain-Associated Behaviors\
(A and B) The cheek model was used to discriminate between pain- (B) and itch-related (A) behaviors. Wiping the cheek with the forepaw following an intradermal injection of a chemical stimulus is indicative of pain, while scratching the injection site with the hindlimb indicates itch.\
(C) Intradermal chloroquine (100 μg) injected into the cheek elicited robust hindlimb-mediated scratching, and this was significantly attenuated in mice pretreated with nalfurafine (20 μg/kg) compared to control.\
(D) Nalfurafine (20 μg/kg) had no significant effect on chloroquine-evoked wiping behavior.\
(E) Intradermal injection of capsaicin (30 μg) into the cheek caused a small amount of hindlimb scratching, which was significantly reduced by nalfurafine (20 μg/kg).\
(F) Nalfurafine (20 μg/kg) had no significant effect on capsaicin-induced wiping. For (C)--(F), data are shown as mean + SEM (n = 8 mice/treatment); ^∗^p \< 0.05, Student's t test; NS indicates no significant effect.](gr5){#fig5}

![Modulation of Kappa Opioid Tone in the Spinal Cord Bidirectionally Modulates Itch Behavior\
(A) The calf model was used to evaluate itch-related behaviors. In this model, a pruritogen is injected into the skin of the calf and biting is indicative of itch.\
(B) Intrathecal administration of 10 μg U-50,488 or 40 ng nalfurafine (doses 60-fold lower than those used above for systemic administration) significantly reduced chloroquine-induced biting. Data are presented as mean + SEM (n = 6--8 mice/treatment). ^∗^ indicates significant difference (p \< 0.05) between treatment and control using one-way ANOVA and Tukey's post hoc test.\
(C) Nalfurafine significantly reduces GRP-induced itch behavior. Intrathecal GRP-evoked scratching behavior was significantly attenuated when GRP (0.1 nmol) was coinjected with nalfurafine (40 ng) compared to PBS. Data are represented as mean + SEM number of scratch bouts recorded over a 30 min observation period (n = 7 mice/treatment). Data were analyzed by a Student's t test; ^∗^ indicates p \< 0.05.\
(D) Molecular structure of two kappa opioid receptor antagonists, norbinaltorphimine (norBNI) and 5′-guanidinonaltrindole (5′GNTI).\
(E) Chloroquine-induced biting was significantly elevated after intrathecal administration of the kappa opioid antagonists 5′GNTI (1 μg) or nor-BNI (1 μg). Data are presented as mean + SEM (n = 6--8 mice/treatment). ^∗^ indicates significant difference (p \< 0.05) between treatment and control using a one-way ANOVA and Tukey's post hoc test.](gr6){#fig6}

![B5-I Neurons Are Innervated by Sensory Neurons that Respond to Capsaicin, Mustard Oil, and Menthol\
(A) *Bhlhb5-cre* neurons were recorded in patch-clamp experiments; fluorescence (left) and IR-DIC (right) image. B5-I neurons had input resistances of 641.7 ± 71.7 MΩ and a resting membrane potential of −63.3 ± 1.4 mV. Every neuron exhibited EPSCs at an average amplitude of 7.9 ± 0.6 pA at a holding potential of −70 mV. No IPSCs were observed because the reversal potential for IPSCs was near −70 mV.\
(B) Representative firing pattern of B5-I neuron in response to depolarizing current pulse of 25 (red) and 100 (black) pA.\
(C) Morphology of B5-I neurons. Neurolucida reconstructions revealed that most B5-I neurons are central (illustrated) or unclassified. Blue, dendrites; red, axons.\
(D) Schematic illustrating experimental setup to test whether B5-I neurons receive input from TrpV1-, TrpA1-, or TrpM8-expressing neurons.\
(E--J) Presynaptic effect of 2 μM capsaicin (E), 100 μM allyl isothiocyanate (mustard oil) (G), and 500 μM menthol (I). The majority of B5-I neurons showed a significant increase in sEPSC frequency after bath application of capsaicin (80%; F), mustard oil (86%; H), and menthol (90%; J). See [Figure S5](#app2){ref-type="sec"} for further electrophysiological analysis of B5-I neurons.](gr7){#fig7}

![B5-I Neurons Mediate Inhibition of Itch by Chemical Counterstimuli\
(A) Mice were treated topically on the cheek with 10 μl of either 8% menthol or PBS (control). Menthol treatment resulted in modest wiping behavior that ceased within 5 min. Ten minutes after initial treatment, chloroquine (100 μg) was injected intradermally into the cheek and hindlimb-mediated scratching was quantified. Menthol significantly reduced subsequent chloroquine-induced scratching behavior in wild-type mice, but not in *Bhlhb5^−/−^* mice. Data are presented as mean + SEM (n = 8 mice/treatment). ^∗^ indicates significant difference (p \< 0.05) between treatment and control using two-way ANOVA and Tukey's post hoc test. Note that there was also a significant difference in chloroquine-induced scratching as a function of genotype, as seen previously ([@bib48]).\
(B) Model: menthol-, capsaicin-, and mustard oil-sensitive sensory neurons inhibit itch via B5-I neurons in dorsal horn. B5-I neurons release GABA and/or glycine, which may cause acute inhibition of itch, as well as dynorphin, which acts as an inhibitory neuromodulator. Though the postsynaptic targets of B5-I neurons are not known, the finding that kappa agonists inhibit GRP-mediated itch implies that kappa opioids act on or downstream of GRPR neurons.](gr8){#fig8}
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